NZ700891A - 4-1bb binding molecules - Google Patents

4-1bb binding molecules

Info

Publication number
NZ700891A
NZ700891A NZ700891A NZ70089111A NZ700891A NZ 700891 A NZ700891 A NZ 700891A NZ 700891 A NZ700891 A NZ 700891A NZ 70089111 A NZ70089111 A NZ 70089111A NZ 700891 A NZ700891 A NZ 700891A
Authority
NZ
New Zealand
Prior art keywords
binding molecules
disclosed
extracellular domain
cdr sequences
binds human
Prior art date
Application number
NZ700891A
Other languages
English (en)
Inventor
Bianca Ahrens
Sangita M Baxi
Simon Paul Bergqvist
Regis Doyonnas
Robert Lee Dufield
Mark William Elliott
Timothy Scott Fisher
Richard Michael Jerome
Heather Laurence Jones
Cris Kamperschroer
Kathrin Ladetzki-Baehs
Victoria Alexandria Love
Theodore Lawrence Oliphant
Adekunle Olatunbosun Onadipe
Wenning Qin
Vinay Radhakrishnan
Allison Karlyn Rohner
Leslie Lynne Sharp
Michael Tesar
Kristin Elizabeth Thomas
Libbey Anne Yates
Daisy Marie Ziegemeier
Moritz Zulley
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to NZ714128A priority Critical patent/NZ714128A/en
Publication of NZ700891A publication Critical patent/NZ700891A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ700891A 2010-09-09 2011-08-26 4-1bb binding molecules NZ700891A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ714128A NZ714128A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38121010P 2010-09-09 2010-09-09
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Publications (1)

Publication Number Publication Date
NZ700891A true NZ700891A (en) 2017-05-26

Family

ID=44759732

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ714128A NZ714128A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NZ714128A NZ714128A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Country Status (27)

Country Link
US (5) US8337850B2 (enExample)
EP (2) EP2614082B1 (enExample)
JP (4) JP6105470B2 (enExample)
KR (2) KR101527300B1 (enExample)
CN (2) CN103221428B (enExample)
AR (2) AR082916A1 (enExample)
AU (3) AU2011300445B2 (enExample)
BR (1) BR112013005699B1 (enExample)
CA (1) CA2810359C (enExample)
CO (1) CO6690759A2 (enExample)
DK (1) DK2614082T3 (enExample)
ES (1) ES2699648T3 (enExample)
HU (1) HUE041958T2 (enExample)
IL (3) IL225001A (enExample)
MX (2) MX337040B (enExample)
MY (2) MY177065A (enExample)
NZ (4) NZ714128A (enExample)
PE (1) PE20131465A1 (enExample)
PH (2) PH12013500395B1 (enExample)
PL (1) PL2614082T3 (enExample)
PT (1) PT2614082T (enExample)
RU (2) RU2551963C2 (enExample)
SG (3) SG10201912092VA (enExample)
SI (1) SI2614082T1 (enExample)
TW (4) TWI652345B (enExample)
WO (1) WO2012032433A1 (enExample)
ZA (1) ZA201502914B (enExample)

Families Citing this family (410)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2614082T3 (en) * 2010-09-09 2018-11-26 Pfizer 4-1BB BINDING MOLECULES
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
CN107964042B (zh) 2012-05-30 2022-04-19 中外制药株式会社 靶组织特异性抗原结合分子
US9834610B2 (en) * 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
US20160264670A1 (en) * 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP3763813A1 (en) 2013-12-04 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
EA032469B1 (ru) 2013-12-24 2019-05-31 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
EP3102604B1 (en) 2014-02-04 2020-01-15 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
CN106413751A (zh) * 2014-05-21 2017-02-15 辉瑞大药厂 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
EP3151820A4 (en) 2014-06-06 2017-11-22 Flexus Biosciences, Inc. Immunoregulatory agents
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CN107921104A (zh) 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
AU2016226468B2 (en) 2015-03-02 2020-10-22 Bristol-Myers Squibb Company TGF-beta inhibitors
CN107207579B (zh) * 2015-03-31 2022-02-25 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
MX2017012729A (es) 2015-04-03 2017-11-15 Bristol Myers Squibb Co Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
JP6971850B2 (ja) 2015-04-13 2021-11-24 ファイヴ プライム セラピューティクス インク がんの併用療法
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
US11008396B2 (en) 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
KR20180042370A (ko) 2015-08-25 2018-04-25 브리스톨-마이어스 스큅 컴퍼니 Tgf 베타 수용체 길항제
CN108026169B (zh) * 2015-09-22 2021-05-28 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
CA3004794A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
KR102738306B1 (ko) 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
JP6783312B2 (ja) * 2016-01-25 2020-11-11 ファイザー・インク がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US10865244B2 (en) 2016-04-18 2020-12-15 Celldex Therapeutics, Inc. Nucleic acids encoding agonistic antibodies that bind CD40
CN109414420A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
EP3452451A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019516681A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
JP2019522627A (ja) 2016-05-04 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
AU2017271601A1 (en) 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
AU2017204125B1 (en) 2016-06-17 2017-10-26 Crispr Therapeutics Ag Compositions and methods for the depletion of cd117+ cells
RU2018142573A (ru) 2016-06-20 2020-07-21 Ф-Стар Бета Лимитед Партнеры по связыванию lag-3
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
MA45672A (fr) 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
MA45941A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
CN106244611B (zh) * 2016-08-23 2019-05-17 浙江普康生物技术股份有限公司 一种细胞免疫佐剂tsa-41的制备方法及应用
JP2019528300A (ja) 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
AU2017332452B2 (en) 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
EP4541423A3 (en) 2016-10-06 2025-06-25 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP7274417B2 (ja) * 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP3565888A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018127787A1 (en) * 2017-01-06 2018-07-12 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
WO2018186924A1 (en) 2017-01-17 2018-10-11 The University Of Chicago Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment
KR102725761B1 (ko) 2017-01-20 2024-11-04 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법
SG11201905812WA (en) 2017-01-20 2019-08-27 Arcus Biosciences Inc Azolopyrimidine for the treatment of cancer-related disorders
CA3053222A1 (en) 2017-02-10 2018-08-16 Genmab B.V. Polypeptide variants and uses thereof
CA3053803A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
US10570138B2 (en) 2017-04-21 2020-02-25 Kyn Therapeutics Indole AHR inhibitors and uses thereof
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP7189155B2 (ja) 2017-05-17 2022-12-13 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体
CA3064331A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
EP4461825A3 (en) 2017-06-09 2024-11-20 Providence Health & Services - Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
EP3645742A4 (en) * 2017-06-25 2021-07-14 Systimmune, Inc. Anti-ror1 antibodies and methods of making and using thereof
IL271601B2 (en) 2017-06-30 2024-05-01 Bristol Myers Squibb Co Amorphous and crystalline forms of ido inhibitors
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
KR102709265B1 (ko) 2017-07-28 2024-09-23 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
CN111182919B (zh) * 2017-08-01 2023-07-07 伊莱利利公司 抗cd137抗体
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
JP7269917B2 (ja) 2017-08-17 2023-05-09 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
EP3676278B1 (en) 2017-08-31 2023-04-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US10953032B2 (en) 2017-08-31 2021-03-23 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7316263B2 (ja) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
CN111344297B (zh) 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CA3075337A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
WO2019072868A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG MULTISPECIFIC ANTIBODIES
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019089753A2 (en) * 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
KR20200074214A (ko) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US20230158141A1 (en) 2017-11-08 2023-05-25 Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd Conjugates of Biomolecule and Use Thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
MX2020004967A (es) 2017-11-17 2020-08-27 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN110003332B (zh) * 2018-01-05 2021-05-11 上海原能细胞医学技术有限公司 Cd137抗体及其应用
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
JP2021509586A (ja) 2018-01-08 2021-04-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍抗原特異的ｔ細胞について濃縮されたｔｉｌ製品を生成するためのプロセス
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
MX2020007543A (es) * 2018-01-15 2020-09-09 Pfizer Metodos para administrar inmunoterapia de receptor de antigeno quimerico en combinacion con agonista 4-1bb.
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
RU2020127196A (ru) * 2018-01-22 2022-02-24 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
SG11202006701TA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
MX2020007797A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7417527B2 (ja) 2018-02-16 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド アゾロピリミジン化合物による投薬
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
KR102874694B1 (ko) 2018-03-21 2025-10-23 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
MA52076A (fr) * 2018-03-23 2021-01-27 Lilly Co Eli Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1
ES2946343T3 (es) * 2018-03-23 2023-07-17 Lilly Co Eli Anticuerpos anti-CD137 para combinación con anticuerpos anti-PD-L1
EP4386080A3 (en) 2018-03-29 2024-12-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
IL297847B2 (en) 2018-04-09 2024-02-01 Origincell Therapeutics Co Ltd Anti-PD-L1 antibody and its use
US12054554B2 (en) 2018-04-10 2024-08-06 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof
KR20200142542A (ko) 2018-04-12 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
PE20210652A1 (es) 2018-04-13 2021-03-26 Hoffmann La Roche Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
EA202190137A1 (ru) 2018-06-27 2021-05-17 Бристол-Маерс Сквибб Компани Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
CA3106366A1 (en) 2018-07-18 2020-01-23 Arcus Biosciences, Inc. Solid forms of an azolopyrimidine compound
US11939381B2 (en) 2018-07-19 2024-03-26 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
CA3107019A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
PL3829581T3 (pl) 2018-07-27 2024-07-01 Arcus Biosciences, Inc. Antagoniści pirydonu a2r
CN112839960B (zh) 2018-08-10 2024-09-06 中外制药株式会社 抗cd137抗原结合分子及其应用
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
JP2022506586A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
AU2019375416A1 (en) 2018-11-05 2021-05-27 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive T-cells
ES3021682T3 (en) 2018-11-05 2025-05-27 Iovance Biotherapeutics Inc Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
TWI828800B (zh) 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
BR112021010402A2 (pt) * 2018-11-30 2021-08-24 Abl Bio Inc. Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
KR20250167680A (ko) 2018-11-30 2025-12-01 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CA3125451A1 (en) * 2019-01-02 2020-07-09 Qlsf Biotherapeutics Inc. Cd137 agonist antibodies and uses thereof
KR20210131312A (ko) * 2019-01-16 2021-11-02 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 항체의 제제 및 이의 용도
CA3124441A1 (en) 2019-02-26 2020-09-03 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
CN113795264A (zh) 2019-03-19 2021-12-14 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION
MX2021011608A (es) 2019-03-29 2021-12-10 Myst Therapeutics Llc Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
KR20220008306A (ko) 2019-05-10 2022-01-20 리브젠 바이오파마 코., 엘티디. 인간화 항-cd137 항체 및 이의 용도
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP2022534889A (ja) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Ｃｄｋ阻害剤を使用した組合せ療法
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
EP3980443A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Multispecific proteins
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
EP4031575A1 (en) 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
EP4034534A1 (en) 2019-09-25 2022-08-03 Pfizer Inc. Polyheterocyclic modulators of sting (stimulator of interferon genes)
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2021093753A1 (zh) 2019-11-13 2021-05-20 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子及其应用
MX2022005839A (es) 2019-11-19 2022-06-09 Bristol Myers Squibb Co Compuestos utiles como inhibidores de la proteina helios.
CN112898426A (zh) * 2019-11-19 2021-06-04 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
CN115151306A (zh) 2019-11-26 2022-10-04 百时美施贵宝公司 (r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
PL4065582T3 (pl) 2019-11-26 2025-08-18 Ikena Oncology, Inc. Polimorficzne pochodne karbazolu i ich zastosowania
CN115023270A (zh) 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
JP7749561B2 (ja) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
IL293351A (en) 2019-12-18 2022-07-01 Pfizer Once daily cancer treatment regimen with a prmt5 inhibitor
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
AU2020412780A1 (en) 2019-12-23 2022-07-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
AU2020415377A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as T cell activators
KR20220120624A (ko) 2019-12-23 2022-08-30 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 피페라진 유도체
EP4081513B1 (en) 2019-12-23 2024-11-20 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
EP4087874A1 (en) 2020-01-06 2022-11-16 HiFiBiO (HK) Limited Anti-tnfr2 antibody and uses thereof
CA3161733A1 (en) 2020-01-07 2021-05-15 Everett Stone Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
US20230054718A1 (en) 2020-01-07 2023-02-23 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
CN115279771B (zh) 2020-01-15 2025-03-21 缆图药品公司 Map4k1抑制剂
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20220144821A (ko) 2020-02-21 2022-10-27 마크로제닉스, 인크. Cd137 결합 분자 및 그것의 용도
IL295990A (en) 2020-02-27 2022-11-01 Myst Therapeutics Llc Methods for in vitro enrichment and expansion of tumor-reactive t cells and preparations related thereto
CN115190889A (zh) * 2020-02-28 2022-10-14 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
CN115151573A (zh) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
EP4112642A4 (en) * 2020-02-28 2024-06-26 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTION AND ITS USE
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
US20240209061A1 (en) 2020-03-09 2024-06-27 Pfizer Inc. Fusion proteins and uses thereof
IL295569A (en) 2020-03-19 2022-10-01 Arcus Biosciences Inc Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
JP2023523855A (ja) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
AU2021271318B2 (en) 2020-05-13 2025-10-30 Pfizer Inc. Methods, therapies and uses for treating cancer
CN116249555A (zh) 2020-05-19 2023-06-09 勃林格殷格翰国际有限公司 用于癌症治疗的结合分子
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
MX2023001217A (es) 2020-07-30 2023-03-03 Kymera Therapeutics Inc Metodos de tratamiento de linfomas mutantes.
MX2023001707A (es) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo específicos para nectina-4 y usos de estos.
MX2023003034A (es) 2020-09-14 2023-04-10 Pfizer Metodos, terapias y usos para tratar el cancer.
CN114195900B (zh) 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN114457026A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
JP2024501207A (ja) 2020-12-16 2024-01-11 ゴッサマー バイオ サービシズ、インコーポレイテッド Ｔ細胞活性化剤として有用な化合物
US20240299539A1 (en) 2020-12-17 2024-09-12 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
JP2024503300A (ja) 2020-12-30 2024-01-25 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
WO2022192145A1 (en) 2021-03-08 2022-09-15 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
BR112023020410A2 (pt) 2021-04-05 2023-11-28 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer
WO2022216644A1 (en) 2021-04-06 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
CA3214952A1 (en) 2021-04-09 2022-10-13 Silvana Marcel LEIT DE MORADEI Cbl-b modulators and uses thereof
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
WO2022236058A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
BR112023022097A2 (pt) 2021-06-07 2023-12-19 Agonox Inc Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AR126442A1 (es) 2021-07-14 2023-10-11 Blueprint Medicines Corp Inhibidores de map4k1
AR126453A1 (es) 2021-07-15 2023-10-11 Blueprint Medicines Corp Inhibidores de map4k1
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
EP4404969A1 (en) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
US20240417482A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Single-domain 4-1bb antibodies
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
JP2024541911A (ja) 2021-10-27 2024-11-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 患者特異的免疫療法のための細胞の製造を調整するためのシステム及び方法
AU2022378630A1 (en) 2021-10-29 2024-05-09 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc HIF-2ALPHA inhibitors and methods of using it
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4469066A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
JP2025504059A (ja) 2022-01-31 2025-02-06 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋデグレーダー及びその使用
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
CN119768401A (zh) 2022-08-11 2025-04-04 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
JP2025526727A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
CR20250043A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados bicíclicos de tetrahidrotiazepina
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
US20240180947A1 (en) 2022-10-20 2024-06-06 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2024143643A1 (ko) 2022-12-30 2024-07-04 앱클론(주) Cd137에 특이적으로 결합하는 어피바디 및 이의 용도
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
KR20250019700A (ko) 2023-05-08 2025-02-10 브리스톨-마이어스 스큅 컴퍼니 치환된 페닐 옥사졸론 화합물
TW202509014A (zh) 2023-05-10 2025-03-01 美商纜圖藥品公司 ＧＳＫ３α抑制劑及其使用方法
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
EP4615455A2 (en) 2023-06-23 2025-09-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202519547A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1x4-1BB抗體及其使用方法
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025032521A1 (en) 2023-08-10 2025-02-13 Pfizer Inc. Methods, therapies and uses for treating cancer
EP4568957A1 (en) 2023-09-02 2025-06-18 Bristol-Myers Squibb Company Substituted phenyl oxooxazolyl piperidine dione compounds
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
AR133800A1 (es) 2023-09-13 2025-11-05 Bristol Myers Squibb Co Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025137370A1 (en) 2023-12-20 2025-06-26 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP1024191B8 (en) 1991-12-02 2008-11-05 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO1996029348A1 (en) 1995-03-23 1996-09-26 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
PL188749B1 (pl) 1996-10-11 2005-04-29 Bristol Myers Squibb Co Zastosowanie przeciwciała anty-4-1BB i kompozycjaleku
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
PT1144607E (pt) 1999-07-20 2009-04-22 Morphosys Ag Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
WO2002055106A2 (en) 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
EP1434596B1 (en) * 2001-10-09 2009-07-08 Mayo Foundation For Medical Education And Research Enhancement of immune responses by agonist 4-1bb-antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US6887673B2 (en) * 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US20060121030A1 (en) 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1827487A2 (en) 2004-11-17 2007-09-05 Board of Regents, The University of Texas System Cancer immunotherapy incorporating p53
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
EP1851244A4 (en) 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
JP2008542354A (ja) 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US8324194B2 (en) 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
KR100745488B1 (ko) 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
EP2083860A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme PCSK9 ANTAGONISTS
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
EP3239178A1 (en) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
WO2009130296A2 (en) 2008-04-25 2009-10-29 Morphosys Ag Anti-alk1 antibodies and uses thereof
US8745699B2 (en) * 2010-05-14 2014-06-03 Authentify Inc. Flexible quasi out of band authentication architecture
AU2010328347B2 (en) 2009-12-07 2015-12-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for enhancing anti-tumor antibody therapy
DK2614082T3 (en) * 2010-09-09 2018-11-26 Pfizer 4-1BB BINDING MOLECULES
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER

Also Published As

Publication number Publication date
JP2019065038A (ja) 2019-04-25
RU2015110632A (ru) 2015-08-10
US8337850B2 (en) 2012-12-25
US20160369000A1 (en) 2016-12-22
CN105481983A (zh) 2016-04-13
PH12020550156A1 (en) 2024-01-15
AR114031A2 (es) 2020-07-15
NZ714128A (en) 2017-10-27
KR101527300B1 (ko) 2015-06-09
PE20131465A1 (es) 2014-01-04
AR082916A1 (es) 2013-01-16
RU2551963C2 (ru) 2015-06-10
JP2022046651A (ja) 2022-03-23
TW201812011A (zh) 2018-04-01
AU2014227437A1 (en) 2014-10-02
PT2614082T (pt) 2018-12-03
KR101527297B1 (ko) 2015-06-26
CN103221428A (zh) 2013-07-24
RU2013110576A (ru) 2014-10-20
JP6105470B2 (ja) 2017-03-29
HK1222872A1 (zh) 2017-07-14
SG10201506906VA (en) 2015-10-29
MY162737A (en) 2017-07-14
MX337040B (es) 2016-02-09
PH12013500395A1 (en) 2013-04-22
JP6557648B2 (ja) 2019-08-07
IL247054A0 (en) 2016-09-29
TWI641621B (zh) 2018-11-21
US20180194851A1 (en) 2018-07-12
SG188313A1 (en) 2013-04-30
CA2810359C (en) 2021-06-22
WO2012032433A1 (en) 2012-03-15
ZA201502914B (en) 2017-08-30
CN105481983B (zh) 2021-09-03
AU2011300445A1 (en) 2013-03-14
US10640568B2 (en) 2020-05-05
EP2614082A1 (en) 2013-07-17
US8821867B2 (en) 2014-09-02
IL250386A0 (en) 2017-03-30
TWI425005B (zh) 2014-02-01
CO6690759A2 (es) 2013-06-17
US20120237498A1 (en) 2012-09-20
KR20130080866A (ko) 2013-07-15
IL225001A (en) 2016-08-31
TW201300413A (zh) 2013-01-01
HUE041958T2 (hu) 2019-06-28
TWI520969B (zh) 2016-02-11
AU2011300445B2 (en) 2014-10-09
RU2710717C2 (ru) 2020-01-10
US20130078240A1 (en) 2013-03-28
PL2614082T3 (pl) 2019-02-28
SG10201912092VA (en) 2020-02-27
CN103221428B (zh) 2016-02-10
IL247054B (en) 2020-06-30
EP2614082B1 (en) 2018-10-03
JP2013544756A (ja) 2013-12-19
US9468678B2 (en) 2016-10-18
BR112013005699B1 (pt) 2021-08-17
SI2614082T1 (sl) 2018-12-31
TW201414748A (zh) 2014-04-16
NZ729044A (en) 2020-07-31
NZ607710A (en) 2014-11-28
BR112013005699A2 (pt) 2017-11-21
EP3441404A1 (en) 2019-02-13
HK1187627A1 (zh) 2014-04-11
MX2013002709A (es) 2013-05-22
RU2015110632A3 (enExample) 2018-11-30
DK2614082T3 (en) 2018-11-26
JP2017075164A (ja) 2017-04-20
MY177065A (en) 2020-09-03
MX374682B (es) 2025-03-06
AU2014227437B2 (en) 2016-07-28
KR20130079533A (ko) 2013-07-10
TW201625694A (zh) 2016-07-16
US20140377255A1 (en) 2014-12-25
ES2699648T3 (es) 2019-02-12
PH12013500395B1 (en) 2020-10-16
TWI652345B (zh) 2019-03-01
AU2018201703A1 (en) 2018-04-05
AU2016204960A1 (en) 2016-08-04
CA2810359A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
NZ729044A (en) 4-1bb binding molecules
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
MX347164B (es) Anticuerpos anti-il-36r.
PH12013500810B1 (en) Anti-il-23 antibodies
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
PH12014502406A1 (en) Anti-il-23p19 antibodies
PH12014502826A1 (en) Immunoconjugates comprising anti-cd79b antibodies
TN2012000462A1 (en) Anti-cd40 antibodies
PH12012501793B1 (en) Monoclonal antibodies against c-met
NZ626610A (en) Antibodies that bind csf1r
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
NZ611785A (en) Anti-notch1 antibodies
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP3019532A4 (en) CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
NZ700274A (en) Anti-pdgf-c antibodies
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
TN2014000207A1 (en) Anti il-36r antibodies
NZ757754A (en) Antibodies that bind csf1r
AU2008904175A0 (en) Improved domain antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 AUG 2018 BY THOMSON REUTERS

Effective date: 20171214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2019 BY THOMSON REUTERS

Effective date: 20180721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2020 BY THOMSON REUTERS

Effective date: 20190725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2021 BY THOMSON REUTERS

Effective date: 20200721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2022 BY THOMSON REUTERS

Effective date: 20210701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2023 BY THOMSON REUTERS

Effective date: 20220704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2024 BY THOMSON REUTERS

Effective date: 20230703

LAPS Patent lapsed